Skip to main content

Japan Patent Office to Grant Patent Covering Dicerna RNAi Constructs

Premium

Dicerna Pharmaceuticals announced this week that the Japan Patent Office has said it intends to grant a patent on an application covering Dicer-substrate technology exclusively licensed by the company.

The intellectual property — No. 2007-504009 — relates to the Dicer-substrate compositions for reducing mammalian target gene expression, regardless of their specific sequence, the company said.

The application stems from the work of City of Hope researcher John Rossi.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.